#NWBO As a physician, there is several reasons why the idea of DCVax-L is exciting. #1. Patient compliance for medication in general is about 50-60%. The higher the side effect profile or burden of treatment, the lower the the compliance rate. DCVax-L immense advantage here.
You know who else hates side effects? Physicians. So when a treatment is given as an intradermal injection (high and known compliance) with such a low side effect profile, its something I am very excited about.
#2. After regulatory approval, you have to ask yourself, will neuro surgeons, neuro oncologist, oncologists be prescribing DCVax-L to their patients? Community physicians typically follow the lead of major academic institutions and thought leaders in their field. See prior post
where I published who was involved.
An impressive list of institutions were involved in this trial.
https://twitter.com/Doc_Hieu/status/1470003816993071104
An impressive list of institutions were involved in this trial.
#3. DCVax will be the foundation for which immuno suppressive combination will likely improve survival per Liau's lectures. Big pharma would love nothing more than to find new indications for their existing medications with upcoming patent cliff.
If you have not read the Pazdur annal of oncology paper in its entirety, I suggest you do, it will make you feel more assured about FDA authorization.
Like I have said before, the price drops do not scare me, it only allows for greater value.
Like I have said before, the price drops do not scare me, it only allows for greater value.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
